Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582618 · ClinicalTrials.gov registry record · Phase 2
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
A Phase 2 study, sponsored by TaiRx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03582618: Clinical Trial Phase 2 study, sponsored by TaiRx.
NCT03582618 is a Phase 2 study that was terminated before completion, run by TaiRx. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03582618, a Phase 2 study, was terminated before completion, sponsored by TaiRx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.
Primary Outcome
Assessment by modified RECIST criteria
Interventions
- DRUG Sorafenib
- DRUG CVM-1118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 2 |
Why NCT03582618 stopped before completion
NCT03582618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT03582618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03582618 about?
NCT03582618 is a clinical study titled "CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma". CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the...
What is the current status of trial NCT03582618?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-07-12. Estimated completion is 2022-12-30.
What interventions are being tested in trial NCT03582618?
The interventions under investigation include: Sorafenib (DRUG), CVM-1118 (DRUG).
Who is sponsoring clinical trial NCT03582618?
This trial is sponsored by TaiRx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03582618's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI